420 related articles for article (PubMed ID: 1486777)
21. Pharmacodynamics of a contraceptive vaginal ring releasing norethindrone and estradiol: ovarian function, bleeding control and lipoprotein patterns.
Victor A; Lithell H; Selinus I; Vessby B
Ups J Med Sci; 1984; 89(2):179-88. PubMed ID: 6380076
[TBL] [Abstract][Full Text] [Related]
22. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
[TBL] [Abstract][Full Text] [Related]
23. Intravaginal contraception with the synthetic progestin, R2010.
Toivonen J
Contraception; 1979 Nov; 20(5):511-8. PubMed ID: 527342
[TBL] [Abstract][Full Text] [Related]
24. Sequential regimen of the antiprogesterone RU486 and synthetic progestin for contraception.
Kekkonen R; Lähteenmäki P; Luukkainen T; Tuominen J
Fertil Steril; 1993 Oct; 60(4):610-5. PubMed ID: 8405512
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the metabolic effects of two hormonal contraceptive methods: an oral formulation and a vaginal ring. II. Serum lipoproteins and apolipoproteins.
Ahrén T; Lithell H; Victor A; Vessby B; Johansson ED
Contraception; 1981 Oct; 24(4):451-68. PubMed ID: 6797786
[TBL] [Abstract][Full Text] [Related]
26. Effect of different insertion regimens on side effects with a combination contraceptive vaginal ring.
Weisberg E; Fraser IS; Lacarra M; Mishell DR; Jackanicz T
Contraception; 1997 Oct; 56(4):233-9. PubMed ID: 9408704
[TBL] [Abstract][Full Text] [Related]
27. Comparative studies of the ethynyl estrogens used in oral contraceptives. VII. Effects with and without progestational agents on ultracentrifugally fractionated plasma lipoproteins in humans, baboons, and beagles.
Goldzieher JW; Chenault CB; de la Peña A; Dozier TS; Kraemer DC
Fertil Steril; 1978 Nov; 30(5):522-33. PubMed ID: 214353
[TBL] [Abstract][Full Text] [Related]
28. Lipid effects of an intrauterine levonorgestrel device or oral vs. vaginal natural progesterone in post-menopausal women treated with percutaneous estradiol.
Suvanto-Luukkonen E; Sundström H; Penttinen J; Kauppila A
Arch Gynecol Obstet; 1998; 261(4):201-8. PubMed ID: 9789651
[TBL] [Abstract][Full Text] [Related]
29. Pharmacodynamic effects of ethinyl estradiol in women using vaginal devices releasing small doses of levonorgestrel at a constant rate.
Toddyvalla V; Johannisson E; Landgren BM; Cekan SZ; Diczfalusy E
Contraception; 1983 Jul; 28(1):21-39. PubMed ID: 6414759
[TBL] [Abstract][Full Text] [Related]
30. A detailed analysis of menstrual blood loss in women using Norplant and Nestorone progestogen-only contraceptive implants or vaginal rings.
Fraser IS; Weisberg E; Minehan E; Johansson ED
Contraception; 2000 Apr; 61(4):241-51. PubMed ID: 10899479
[TBL] [Abstract][Full Text] [Related]
31. Vaginal bleeding patterns among women using one natural and eight hormonal methods of contraception.
Belsey EM
Contraception; 1988 Aug; 38(2):181-206. PubMed ID: 2971505
[TBL] [Abstract][Full Text] [Related]
32. Vaginal epithelial surface appearances in women using vaginal rings for contraception.
Fraser IS; Lacarra M; Mishell DR; Alvarez F; Brache V; Lähteenmäki P; Elomaa K; Weisberg E; Nash HA
Contraception; 2000 Feb; 61(2):131-8. PubMed ID: 10802278
[TBL] [Abstract][Full Text] [Related]
33. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.
Kalogirou D; Antoniou G; Karakitsos P; Kalogirou O; Antoniou D; Giannikos L
Int J Fertil Menopausal Stud; 1996; 41(6):522-7. PubMed ID: 9010746
[TBL] [Abstract][Full Text] [Related]
34. Fasting plasma lipids, lipoproteins and apolipoproteins in Nigerian women using combined oral and progestin-only injectable contraceptives.
Oyelola OO
Contraception; 1993 May; 47(5):445-54. PubMed ID: 8513671
[TBL] [Abstract][Full Text] [Related]
35. Serum concentrations of estradiol, progesterone, and levonorgestrel are not determinants of endometrial histology or abnormal bleeding in long-term Norplant implant users.
Darney PD; Taylor RN; Klaisle C; Bottles K; Zaloudek C
Contraception; 1996 Feb; 53(2):97-100. PubMed ID: 8838486
[TBL] [Abstract][Full Text] [Related]
36. Vaginal rings for contraception: endocrine parameters.
Olsson SE
Adv Contracept Deliv Syst; 1992; 8(1-2):71-3. PubMed ID: 12285565
[TBL] [Abstract][Full Text] [Related]
37. Ovarian function, bleeding control and serum lipoproteins in women using contraceptive vaginal rings releasing five different progestins.
Ahrén T; Victor A; Lithell H; Vessby B; Jackanicz TM; Johansson ED
Contraception; 1983 Oct; 28(4):315-27. PubMed ID: 6667620
[TBL] [Abstract][Full Text] [Related]
38. Comparative study on intermittent versus continuous use of a contraceptive pill administered by vaginal route.
Coutinho EM; O'Dwyer E; Barbosa IC; Gu ZP; Shaaban MM; Aboul-Oyoon M; Abdel Aleem H
Contraception; 1995 Jun; 51(6):355-8. PubMed ID: 7554976
[TBL] [Abstract][Full Text] [Related]
39. The effect of transdermal oestradiol on bleeding pattern, hormonal profiles and sex steroid receptor distribution in the endometrium of Norplant users.
Boonkasemsanti W; Reinprayoon D; Pruksananonda K; Niruttisard S; Triratanachat S; Leepipatpaiboon S; Wannakrairot P
Hum Reprod; 1996 Oct; 11 Suppl 2():115-23. PubMed ID: 8982753
[TBL] [Abstract][Full Text] [Related]
40. The hormonal ring. A new contraceptive gains acceptance.
Hardy EE; Reyes Q; Gomez F; Portes-carrasco R; Faundes A
IDRC Rep; 1984 Jul; 13(2):11. PubMed ID: 12313242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
